Fast-Growing European Market for Molecular Diagnostics

Molecular diagnostics is one of the fastest growing areas in the European in vitro diagnostics (IVD) market. To maximize the tremendous growth potential of molecular diagnostics, market participants will need to effectively communicate with healthcare providers and keep them updated on technologic advancements as well as the availability of new tests.

According to a new report from Frost & Sullivan (Palo Alto, CA, USA), the European molecular diagnostics market earned revenues of U.S.$517.5 million in 2005, which are estimated to reach $987.5 million in 2012.

"Early diagnosis and technological superiority over immunoassays are the key factors driving the wider adoption of molecular tests in Europe,” noted AK Arun, a research associate at Frost & Sullivan. "An emphasis on enhanced patient care, better therapeutic options, and population-screening programs are boosting the uptake of tests.”

Automated and integrated molecular diagnostic solutions are improving assay performance by decreasing the complexity involved in a molecular test. Despite the relatively high price of molecular tests, the inherent benefits, including reduced labor requirements and low cost per assay, will support their adoption.

”However, market success will depend to a large extent on effective communication,” cautioned Mr. Arun. "Manufacturers will need to communicate the value of their technologies to healthcare regulators, payers, providers and patients.”

Many molecular diagnostic assays are novel in the information they provide to the physician and the patient. Therefore, creating awareness and educating healthcare providers and patients alike will be necessary both for the success of the assay and also to qualify for reimbursement.

"Molecular diagnostics companies must conduct awareness programs aimed at educating physicians on developments in pharmacogenomics and cancer diagnosis, in addition to infectious disease screening,” advised Mr. Arun. "As recommendations by physicians and cancer association groups strongly influence the adoption of molecular tests, such awareness programs will be critical to the success of manufacturers.”



Related Links:
Frost & Sullivan